CLL
Conference Coverage
Venetoclax plus ibrutinib yields encouraging MRD results in first-line CLL
CHICAGO – The drug combination was evaluated in a phase 2 study of patients with previously untreated CLL.
From the Journals
Older CLL and NHL patients are more vulnerable to toxicities
These toxicities led to worse survival for older patients with non-Hodgkin lymphoma.
From the Journals
5-year data show deepening response with ibrutinib in CLL
The long-term findings don’t raise red flags about safety with the drug in CLL.
From the Journals
Venetoclax shows muscle against CLL relapsed after idelalisib
The BCL-2 inhibitor venetoclax may be an effective follow-on to a B cell receptor pathway inhibitor.
From the Journals
Updated CLL guidelines incorporate a decade of advances
Advances in genomics, diagnostics and therapies since 2008 are reflected in the guidelines.
From the Journals
Experimental voxtalisib shows mixed results in phase 2 study
The novel pan-P13K/mTOR inhibitor induced complete responses in some patients with follicular lymphoma, but not aggressive malignancies, including...
From the Journals
A global snapshot of leukemia incidence
United States is on the high side for all four subtypes of the disease.
From the Journals
Ibrutinib linked to invasive fungal infections
The researchers called for greater awareness of the potential for fungal infection in ibrutinib-treated patients.
From the Journals
Baseline stress signals need for psychological help in CLL
Be on the lookout for cancer-specific stress when treating chronic lymphocytic leukemia.
From the Journals
CLL Index proves accurate in predicting survival, time to treat
A meta-analysis shows that the CLL-IPI is a useful tool with chemoimmunotherapy, but data is lacking about its use with targeted therapies.
Conference Coverage
VIDEO: Practice changers out of ASH 2017
ATLANTA – Dr. Robert Brodsky shares his takeaways on the key practice changing data presented in the ASH 2017 late breakers.